Congleton Jon — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Congleton Jon has filed 5 SEC Form 4 filings across 3 companies in the last 90 days — selling. Lifetime open-market sales: $5.73M.

Profile

Jon Congleton is the Chief Executive Officer and a Director of Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for diseases related to elevated aldosterone levels. He has been involved in the company through multiple SEC filings, indicating his active role in corporate governance.

Board memberships

• Mineralys Therapeutics, Inc.

Awards & honors

• CEO of Mineralys Therapeutics
• Director at Mineralys Therapeutics

Recent Transactions

Companies — Last 90 Days

• Mineralys Therapeutics, Inc. (MLYS) — 2 filings, last 2026-07-16
• IMMUNIC, INC. (IMUX) — 2 filings, last 2026-07-07
• Avalyn Pharma Inc. (AVLN) — 1 filings, last 2026-05-01

Frequently Asked Questions

Who is Congleton Jon?

Jon Congleton is the Chief Executive Officer and a Director of Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for diseases related to elevated aldosterone levels. He has been involved in the company through multiple SEC filings, indicating his active role in corporate governance.…

How many SEC Form 4 filings has Congleton Jon submitted recently?

5 primary Form 4 filings in the last 90 days, covering 3 companies.

Has Congleton Jon been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 11 open-market sales ($5.73M) across all tracked filings.

Where can I see all of Congleton Jon's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

• What is SEC Form 4?
• How to read insider buying signals
• Understanding Rule 10b5-1 trading plans
• Browse all insiders
• Most active insiders this week